Can-Fite Stock Jumps After Japan Patent Boosts Obesity Drug Case

▤ Summary

Can-Fite received a Japanese patent allowance covering A3 adenosine receptor agonists, including Namodenoson, for fat loss and obesity-related metabolic disorders. The company said the patent strengthens its intellectual property position in Japan, where it already has protection in the United States, Canada, Australia, and Israel. Can-Fite also cited research supporting Namodenoson’s anti-obesity activity and its broader potential in metabolic disease. The drug remains in development across oncology and MASH programs, and the company framed the patent as a support for future partnering opportunities.

▦ Linked Companies